contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


year-end-report-january-december-2024-combigene-ab-publ

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

CombiGene

October – December 2024Net sales: 0 (596) TSEK.Other operating income: 1,962 (875) TSEK.Result after financial items: -14,157 (-6,360) TSEK.Earnings per share: -0.71 SEK (-0.32). January – December...

<div class="mfn-body">October – December 2024<ul><li>Net sales: 0 (596) TSEK.</li><li>Other operating income: 1,962 (875) TSEK.</li><li>Result after financial items: -14,157 (-6,360) TSEK.</li><li>Earnings per share: -0.71 SEK (-0.32).</li></ul>&nbsp;January – December 2024<ul><li>Net sales: 326 (5,544) TSEK.</li><li>Other operating income: 3,274 (1,464) TSEK.</li><li>Result after financial items: -44,878 (-35,665) TSEK.</li><li>Earnings per share: -2.27 SEK (-1.80).</li><li>Cash and cash equivalents at the end of the period: 73,748 (101,440) TSEK.</li></ul>Events during the fourth quarter of 2024 • CombiGene initiates measures to extend the liquidity horizon by sharpening the strategic focus on gene therapy, prioritizing pipeline assets, and implementing a cost reduction program. • CombiGene holds an extraordinary general meeting. The meeting decided, in accordance with the shareholder Strategic Partner A/S’s proposal, that the board should consist of three ordinary board members with one deputy board member. Luca Di Stefano and Jakob Bendtsen were elected, and Marcus Isaksson was re-elected, as board members. Furthermore, Lars Thunberg was elected as a new deputy board member. The meeting also decided, in accordance with the shareholder Strategic Partner A/S’s proposal, to amend the articles of association. The amendment was made to expand the business purpose, allowing the company to enter strategic partnerships with other companies in other industries.Events after the end of the period • CombiGene AB initiates restructuring as part of a strategic review to maximize shareholder value and terminates all employment, including the CEO. The severance cost for the staff is estimated to amount to approximately SEK 6.8 million. • CombiGene AB discontinues all activities and collaborations linked to research. The winding-up cost for operations and projects is estimated to amount to SEK 0.9 million.</div><div class="mfn-footer mfn-contacts mfn-954154356e40">Contacts<hr>CombiGene AB (publ) Luca Di Stefano, Chairman of the Board Phone: +46 (0)70 855 67 23 luca.distefano@combigene.com<a rel="noopener" href="https://combigene.com/">www.combigene.com</a> CombiGene AB (publ),&nbsp;Skeppsbron 38, SE-111&nbsp;30&nbsp;Stockholm, Sweden +46-8-357355 <a rel="noopener" href="mailto:info@combigene.com">info@combigene.com</a></div><div class="mfn-footer mfn-about mfn-2840449e81ce">About CombiGene<hr>The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is Västra Hamnen Corporate Finance AB.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/15158837-a568-49b9-aa4e-431e2a88a09a/combigene-q4-2024-eng.pdf" class="mfn-primary">CombiGene Q4 2024 ENG</a></div>